Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZYXI
stocks logo

ZYXI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
25.53M
-44.47%
-0.110
+450%
25.95M
-2.36%
-0.110
-66.67%
24.74M
+10.99%
-0.110
-83.33%
Estimates Revision
The market is revising Upward the revenue expectations for Zynex, Inc. (ZYXI) for FY2025, with the revenue forecasts being adjusted by 4.38% over the past three months. During the same period, the stock price has changed by -30.87%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.38%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.3%
In Past 3 Month
Stock Price
Go Down
down Image
-30.87%
In Past 3 Month
Wall Street analysts forecast ZYXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYXI is USD with a low forecast of 3.70 USD and a high forecast of 3.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ZYXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYXI is USD with a low forecast of 3.70 USD and a high forecast of 3.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 1.030
sliders
Low
3.70
Averages
High
3.70
Current: 1.030
sliders
Low
3.70
Averages
High
3.70
H.C. Wainwright
Yi Chen
Buy -> Neutral
downgrade
2025-08-01
Reason
H.C. Wainwright
Yi Chen
Price Target
2025-08-01
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Yi Chen downgraded Zynex to Neutral from Buy without a price target. The company reported a Q2 miss and an operational restructuring is in progress, the analyst tells investors in a research note. The firm says there is no visibility at this point as to when Tricare payments to Zynex will resume.
Ladenburg
Neutral -> Buy
upgrade
$3.70
2025-08-01
Reason
Ladenburg
Price Target
$3.70
2025-08-01
upgrade
Neutral -> Buy
Reason
Ladenburg upgraded Zynex to Buy from Neutral with a $3.70 price target.
Ladenburg
Neutral -> Buy
upgrade
$3.70
2025-08-01
Reason
Ladenburg
Price Target
$3.70
2025-08-01
upgrade
Neutral -> Buy
Reason
As previously reported, Ladenburg upgraded Zynex to Buy from Neutral with a $3.70 price target. While the firm recognizes disruptions in the pain segment are "material," creating uncertainty and negatively impacting the company's performance, it argues that the opportunity for the NiCO laser pulse oximeter "should not be overlooked," citing the differentiated technology and agency-driven efforts to provide more equitable care.
RBC Capital
Sector Perform
downgrade
$4 -> $3
2025-07-15
Reason
RBC Capital
Price Target
$4 -> $3
2025-07-15
downgrade
Sector Perform
Reason
RBC Capital lowered the firm's price target on Zynex to $3 from $4 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 results for MedTech names. Based on the firm's intra-quarter diligence with key opinion leaders and company management / investor discussions, there is a high level of interest in MedTech and multiple opportunities across the sector, the analyst tells investors in a research note. Regarding the company however, the firm notes that sentiment on the stock is quite negative given its Q1 miss and no guidance issued for 2025.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$17 → $15
2025-03-12
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$17 → $15
2025-03-12
Maintains
Strong Buy
Reason
Ladenburg Thalmann
Jeffrey Cohen
Strong Buy
to
Hold
Downgrades
n/a
2025-03-12
Reason
Ladenburg Thalmann
Jeffrey Cohen
Price Target
n/a
2025-03-12
Downgrades
Strong Buy
to
Hold
Reason
Ladenburg downgraded Zynex to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue pressure.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zynex Inc (ZYXI.O) is -2.64, compared to its 5-year average forward P/E of 21.67. For a more detailed relative valuation and DCF analysis to assess Zynex Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
21.67
Current PE
-2.64
Overvalued PE
36.44
Undervalued PE
6.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.76
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
20.85
Undervalued EV/EBITDA
0.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.90
Current PS
0.00
Overvalued PS
2.94
Undervalued PS
0.86
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ZYXI News & Events

Events Timeline

(ET)
2025-11-14
08:18:15
Zynex unveils a set of strategic initiatives to explore various options.
select
2025-08-18 (ET)
2025-08-18
08:17:30
Zynex Reveals Newly Appointed Executive Team
select
2025-07-31 (ET)
2025-07-31
16:16:04
Zynex suspends guidance
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-28Benzinga
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.

  • Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.

  • Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.

  • Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.

[object Object]
Preview
2.0
11-27TipRanks
Three Penny Stocks to Keep an Eye On as of November 27, 2025

  • Penny Stocks to Watch: Zynex Inc., Amber International Holding, and Pasithea Therapeutics are highlighted as top penny stocks to monitor on November 27, 2025, based on their high Dollar Volume and significant stock price increases.

  • Zynex Inc. Performance: Zynex, a MedTech company, experienced a 115% stock price surge with a Dollar Volume of $224.62 million, despite no specific news driving the increase.

  • Amber International Holding Update: Amber International, a digital wealth management platform, saw its stock price rise by 56% following a $50 million share repurchase announcement and strong Q3 earnings results, with a Dollar Volume of $222.02 million.

  • Pasithea Therapeutics Grant: Pasithea Therapeutics, focused on CNS disorders, reported a 117% stock price increase and a Dollar Volume of $169.09 million after receiving a $1 million grant from the ALS Association for its drug PAS-004.

[object Object]
Preview
9.5
11-20NASDAQ.COM
Earnings Growth Boosts PACS and Nutex; Zynex and Genenta Also Rise in After-Hours Trading

  • PACS Group Performance: PACS Group Inc. saw a significant after-hours surge of 45.48% to $24.48, following a strong quarterly report showing a net income increase to $52.4 million and revenue growth to $1.345 billion.

  • Zynex, Inc. Update: Zynex, Inc. experienced a 4.49% rise after hours to $0.58, despite reporting a net loss of $42.9 million for the quarter, down from a profit in the same period last year.

  • Genenta Science Recovery: Genenta Science S.p.A. rose 7.34% after hours to $1.90, recovering from a previous decline, with no new updates but a recent securities purchase agreement raising approximately $15 million.

  • Nutex Health Growth: Nutex Health Inc. advanced 9.64% after hours to $123.00, following a strong quarterly performance with a net income of $55.4 million and a revenue increase of 239.9% to $267.8 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zynex Inc (ZYXI) stock price today?

The current price of ZYXI is 1.03 USD — it has decreased -11.21 % in the last trading day.

arrow icon

What is Zynex Inc (ZYXI)'s business?

Zynex, Inc. is a medical technology company specialized in the manufacturing and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The Company’s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.

arrow icon

What is the price predicton of ZYXI Stock?

Wall Street analysts forecast ZYXI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYXI is  USD with a low forecast of 3.70 USD and a high forecast of 3.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zynex Inc (ZYXI)'s revenue for the last quarter?

Zynex Inc revenue for the last quarter amounts to 13.36M USD, decreased -73.26 % YoY.

arrow icon

What is Zynex Inc (ZYXI)'s earnings per share (EPS) for the last quarter?

Zynex Inc. EPS for the last quarter amounts to -1.42 USD, decreased -2128.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zynex Inc (ZYXI)'s fundamentals?

The market is revising Upward the revenue expectations for Zynex, Inc. (ZYXI) for FY2025, with the revenue forecasts being adjusted by 4.38% over the past three months. During the same period, the stock price has changed by -30.87%.
arrow icon

How many employees does Zynex Inc (ZYXI). have?

Zynex Inc (ZYXI) has 1000 emplpoyees as of December 05 2025.

arrow icon

What is Zynex Inc (ZYXI) market cap?

Today ZYXI has the market capitalization of 31.30M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free